Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Authors :: Jeffrey Weber
Paolo A. Ascierto
Sonia Dolfi
Hao Tang
Margarita Askelson
Maurice Lobo
Corey Ritchings
Paola Queirolo
Nikhil I. Khushalani
Paul D. Nathan
Michael Millward
Leslie A. Fecher
Andrew G. Hill
Victoria Atkinson
Petr Arenberger
Luis de la Cruz-Merino
Jose Lutzky
Mark R. Middleton
Anna Maria Di Giacomo
Marcus O. Butler
Ivan Marquez-Rodas
Vanna Chiarion-Sileni
Jean-Jacques Grob
Michael Schenker
Charles Lance Cowey
Stéphane Dalle
Ana M. Arance Fernandez
Helen Gogas
Mario Mandalá
Michele Del Vecchio
James Larkin
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238

Tools